Versant Venture Management, LLC Long-Term Concentrated

Location: San Francisco, CA

CIK: 0001560009 · Show all filings

Period: Q4 2024 (← Previous) (Next →)

Filing Date: Feb 12, 2025

Total Value: $86.75M (100.0% shares, 0.0% debt)

Holdings (7)

GLUE Monte Rosa Therapeutics, Inc. 45.2%

Value $39.23M Shares 5,652,922 Est. Cost $7.50 Unrealized 0.0%

CRSP CRISPR Therapeutics AG 22.6%

Value $19.62M Shares 498,558 Est. Cost $40.26 Unrealized +17.3%

CTNM Contineum Therapeutics, Inc. 15.5%

Value $13.45M Shares 918,163 Est. Cost $16.10 Unrealized -1.7%

SKYE Skye Bioscience, Inc. 6.5%

Value $5.682M Shares 2,007,704 Est. Cost $7.75 Unrealized -46.1%

— Repare Therapeutics, Inc. 4.0%

Value $3.467M Shares 2,646,657 Est. Cost $10.58 Unrealized —

— Tempest Therapeutics, Inc. 3.4%

Value $2.927M Shares 3,507,055 Est. Cost $0.83 Unrealized —

— Adverum Biotechnologies, Inc. 2.7%

Value $2.367M Shares 506,821 Est. Cost $9646.10 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
GLUE	Monte Rosa Therapeutics, Inc.	5,652,922	$39.23M	45.2%	$7.50	0.0%	Common Stock	61225M102
CRSP	CRISPR Therapeutics AG	498,558	$19.62M	22.6%	$40.26	+17.3%	Common Shares	H17182108
CTNM	Contineum Therapeutics, Inc.	918,163	$13.45M	15.5%	$16.10	-1.7%	Common Stock	21217B100
SKYE	Skye Bioscience, Inc.	2,007,704	$5.682M	6.5%	$7.75	-46.1%	Common Stock	83086J200
—	Repare Therapeutics, Inc.	2,646,657	$3.467M	4.0%	$10.58	—	Common Stock	760273102
—	Tempest Therapeutics, Inc.	3,507,055	$2.927M	3.4%	$0.83	—	Common Stock	87978U108
—	Adverum Biotechnologies, Inc.	506,821	$2.367M	2.7%	$9646.10	—	Common Stock	00773U108